Therefore, low PgR expression, which is routinely measured in clinical practice, likely represents a high-risk factor that may be used as a potential surrogate marker for GATA3 mutation in patients with ER-positive DCIS. This evidence concerns the gene PGR and ductal breast carcinoma in situ.